Tumor Heterogeneity and Drug Resistance Mutations Using ctDNA in Metastatic EGFR Mutation-Positive Lung Adenocarcinoma: A Case Report

For advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, EGFR tyrosine kinase inhibitors (TKIs) have been approved as the standard therapy and shown clinical benefits. However, the emergence of drug resistance is inevitable. Tumor heterogeneity...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jinghua, Sun, Ge, Lu, KeMou, Xu, Lingling, Qu, XiaoNa, Cheng, Ye, Pan, Evenki, Yang, Peng, Wu, Tingting, Zhang, Yang, He, HongMei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440701/
https://www.ncbi.nlm.nih.gov/pubmed/36065405
http://dx.doi.org/10.2147/OTT.S376647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440701/
https://www.ncbi.nlm.nih.gov/pubmed/36065405
http://dx.doi.org/10.2147/OTT.S376647

Ejemplares similares